Haemonetics Corp. (HAE) Tops Q3 EPS by 6c; Affirms FY12 EPS Outlook
Tweet
Share
E-mailGet Alerts HAE Hot Sheet
Price: $72.53 -2.21%
EPS Growth %: -0.9%
Financial Fact:
Net revenues: 220.25M
Today's EPS Names:
OCCI, MAYS, CRMT, More
EPS Growth %: -0.9%
Financial Fact:
Net revenues: 220.25M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
Haemonetics Corp. (NYSE: HAE) reported Q3 EPS of $0.86, $0.06 better than the analyst estimate of $0.80. Revenue for the quarter came in at $191.2 million versus the consensus estimate of $186.21 million.
Affirms outlook.
For earnings history and earnings-related data on Haemonetics Corp. (HAE) click here.
Affirms outlook.
For earnings history and earnings-related data on Haemonetics Corp. (HAE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Goldman reinstates Estee Lauder rating, sees turnaround driving growth and margins
- NVE Corporation names new CEO and expands board to seven members
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
